一项关于胃病变与重型猪抗炎药物使用之间的关系的初步研究
Sergio Ghidini1, Federico Scali2, Claudia Romeo2
1Department of Food and Drug, University of Parma, Strada del Taglio 10, 43126 Parma, Italy.
Veterinary sciences
|September 27, 2023
概括
研究了意大利重型猪胃病变的发生率. 非类固醇抗炎药物 (NSAID) 的使用与这些病变有积极的关联,建议谨慎使用.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 动物科学动物科学
- 胃肠病学 胃肠病学
背景情况:
- 猪的胃病变导致了严重的福利和经济损失,特别是在用于优质产品的重型猪中.
- 虽然压力,营养和农场管理是已知的危险因素,但抗炎药物对胃健康的影响仍未得到充分探索.
研究的目的:
- 为了确定意大利重型猪胃病变的患病率.
- 调查使用类固醇和非类固醇抗炎药物 (NSAID) 与胃病变发生之间的潜在关联.
主要方法:
- 评估来自76个农场的9371个猪胃,以评估损伤的流行率和严重程度.
- 在36个农场的子集上计算NSAID和类固醇每1000人治疗发病率 (TI_1000),以估计药物使用率.
- 统计分析以确定药物使用和胃损伤得分之间的相关性.
主要成果:
- 观察到胃病变的明显流行率,其中79.7%的胃显示出一定程度的损伤.
- 非类固醇抗炎药物 (NSAID) 的使用与更高的胃损伤得分有关.
- 类固醇使用与胃病变严重程度没有显著的关联.
结论:
- 这项研究强调了NSAID管理与意大利重型猪的胃病变之间的联系.
- 研究结果表明,需要仔细考虑和明智地使用非选择性NSAIDs在猪生产中,以减轻胃损伤.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
478
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
478
Peptic Ulcer Disease IV: Management
109
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
109
Gastritis III: Clinical Manifestations and Management
314
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
314
Peptic Ulcer Disease I: Introduction
192
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
192
Gastritis-II: Pathophysiology
367
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
367
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
154
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
154


